Use only the exact product’s intended route.
Mouth lozenges must dissolve slowly and are not systemic antifungal therapy. Vaginal symptoms without a previous clinician diagnosis, recurrent symptoms or fever/pain need assessment. Clotic is for adults with intact eardrums; do not use skin/vaginal preparations as an ear substitute.
Warnings and precautionsIndications
Local fungal infection requires the right diagnosis and route.
Mouth and skin indications
Lozenges: local oropharyngeal candidiasis, confirmed by KOH/culture; prophylaxis in specified chemotherapy/radiotherapy/steroid-associated leukemia, solid-tumor or renal-transplant contexts. Other immunocompromised prophylaxis lacks adequate evidence; not systemic mycoses. Prescription 1% skin cream: Candida albicans skin candidiasis and Malassezia furfur tinea versicolor. OTC 1% skin cream treats athlete’s foot, jock itch and ringworm; not scalp/nail infection.
Vaginal and otic indications
Vaginal 1%/2% creams treat vaginal yeast infection and associated external vulvar itching; self-use requires a previous clinician diagnosis. Clotic treats Aspergillus/Candida fungal otitis externa in adults ≥18; studied with intact tympanic membranes, and not recommended with perforation. Other skin solutions or steroid combinations have separate labeling and are not substituted.
Dosage and administration
Route-specific courses range from 3 to 14 days.
Mouth and skin regimens
| Product | Selected labeled dose |
|---|---|
| 10 mg mouth lozenge | Dissolve 1 slowly five times daily for 14 days for oropharyngeal treatment. Below 3 not recommended; ability to follow dissolution instructions required. |
| Specified prophylaxis | 1 lozenge three times daily during chemotherapy or until steroids reach maintenance; pediatric prophylactic safety/efficacy unestablished. Prefer short-term use when possible because prolonged data are limited. |
| Prescription 1% skin cream | Massage sufficient cream into affected/surrounding skin twice daily, morning/evening. No improvement after 4 weeks requires diagnosis review. |
| OTC 1% skin cream | Clean/dry skin, thin layer twice daily. Athlete’s foot/ringworm 4 weeks; jock itch 2 weeks. Below 2 years ask a doctor; supervise children. |
Vaginal and otic regimens
| Product | Selected labeled regimen |
|---|---|
| Vaginal 1%, age ≥12 | 1 applicatorful (50 mg) at bedtime for 7 days. Selected reusable applicator washed after use. |
| Vaginal 2%, age ≥12 | 1 applicatorful (100 mg) at bedtime for 3 days. Selected disposable applicator discarded after each use. |
| External vulvar relief | Small amount from selected vaginal cream twice daily up to 7 days as needed; not a replacement for intravaginal course. Below 12 ask a doctor. |
| Clotic, adults ≥18 | Entire single-dose vial into affected ear twice daily, preferably 12 hours apart, for 14 days. Warm vial in hand 1–2 minutes; affected ear up, gently pull ear up/out and remain 1 minute. |
Adjustment and preparation limits
No numerical renal/hepatic adjustment or dialysis supplementation is supplied for these selected local products. Mouth lozenges should not be chewed or swallowed whole as conventional systemic tablets; allow slow dissolution. Skin products are not for eyes. Use the actual applicator/device and full Clotic vial, not an inferred drop count or interchangeable solution.
Safety
Local allergy, liver effects from lozenges and diagnostic delay matter.
Warnings and precautions
- Stop for hypersensitivity or marked local irritation; spreading rash/hives or breathing difficulty requires urgent assessment.
- Lozenges: abnormal liver tests reported; periodic hepatic assessment is advisable, particularly with pre-existing impairment. Patient must be able to understand/perform slow dissolution. Do not use for systemic mycoses.
- Skin cream: avoid eyes and occlusive dressings; increased redness, burning, blistering, swelling or oozing can indicate sensitization. Review nonresponse rather than repeat blindly.
- Vaginal self-use: first-ever symptoms, recurrent infections, HIV exposure or fever/abdominal/back/shoulder pain, vomiting or foul discharge need clinician review. Stop/review if no improvement in 3 days or symptoms persist>7 days.
- Vaginal cream may damage condoms/diaphragms; avoid vaginal intercourse, tampons, douches, spermicides and other vaginal products during treatment.
- Clotic: use only in ear as prescribed; not recommended with perforated tympanic membrane. Adult label section 5 says no additional warnings; this does not remove its route/indication limits or potential local adverse effects.
Contraindications
Lozenge and prescription skin cream: component hypersensitivity. Clotic: known clotrimazole hypersensitivity. OTC vaginal Drug Facts prohibits self-use without a previous clinician-diagnosed vaginal yeast infection; under 12 requires a doctor. Product-specific restrictions are not generalized into one universal age contraindication.
Boxed warning / status
No boxed warning appears in the selected single-ingredient labels. Some products are prescription and others OTC; absence of a box does not establish safe route substitution, systemic infection treatment or unrestricted self-treatment.
Adverse reactions and overdose
Lozenges can cause nausea, vomiting, unpleasant mouth sensation, itching and elevated liver tests. Skin/vaginal products may cause local burning, itching, irritation or allergic skin reactions. Clotic trial reports include headache, application-site pain, tinnitus, tympanic-membrane perforation and paresthesia. Lozenges have no label overdose data; topical overdose is considered unlikely, but swallowed local products require Poison Control/medical advice. No home antidote or guaranteed harmless-ingestion claim.
Drug interactions
Mouth lozenges may affect transplant-drug exposure despite local intent.
Tacrolimus interaction
Current Prograf label identifies clotrimazole as a mild/moderate CYP 3 A inhibitor that can raise tacrolimus trough concentrations and serious toxicity risk. Transplant teams monitor troughs and adjust tacrolimus if needed; monitoring also matters when an interacting medicine is stopped. This supports review especially for mouth-lozenge use, not an invented identical systemic exposure from every skin/vaginal/otic product.
Local product considerations
Vaginal creams can impair condoms/diaphragms and should not be combined with other vaginal products during treatment. Selected skin/otic labels do not provide a complete clinical drug-interaction algorithm; limited topical absorption is not proof every combination is studied. Avoid independent steroid-combination or oral-antifungal substitution.
Use in specific populations
Pediatric limits differ by mouth, skin, vaginal and ear products.
Children and older adults
Lozenges below 3 are not recommended; pediatric prophylaxis is unestablished and slow-dissolution ability is essential. OTC skin product below 2 needs a doctor; prescription cream establishes pediatric use as indicated. Vaginal self-use≥12; younger children need diagnosis/prescriber review. Clotic below 18 is unestablished. Lozenge older-adult evidence is limited; Clotic trials found no overall age-related difference but greater sensitivity cannot be excluded.
Renal and hepatic considerations
No validated numeric organ adjustment is supplied. Lozenges can elevate liver enzymes: assess hepatic function periodically, especially with prior impairment. Transplant recipients taking tacrolimus need interaction/level review; local antifungal therapy does not itself establish renal safety of co-medications. No inferred systemic half-life-based adjustment.
Pregnancy and lactation
Lozenge adequate pregnancy studies are absent; use only if benefit justifies fetal risk. Skin cream has low absorption, but first-trimester evidence is limited and human milk excretion unknown. Vaginal Drug Facts requires professional advice if pregnant/breastfeeding. Clotic expects minimal systemic absorption/fetal or infant exposure, while patient information acknowledges uncertainty; consider maternal need and breastfeeding benefits. No universal pregnancy-letter-category reassurance or identical reproductive conclusion across routes.
Clinical pharmacology
Fungal membrane sterol disruption produces local antifungal activity.
Mechanism
Azole inhibition of lanosterol 14-alpha-demethylase disrupts ergosterol synthesis and fungal membrane integrity. Activity/resistance depends on organism and site; do not turn in-vitro susceptibility into a universal infection indication.
Pharmacokinetics
Lozenges dissolve over approximately 30 minutes and retain inhibitory salivary levels for up to 3 hours; measured serum levels are low. Dermal/vaginal absorption is limited. Clotic plasma concentrations were not measured in the labeled regimen; minimal absorption is anticipated, not a measured numeric bioavailability. No validated universal elimination half-life or serum target is supplied for these local products.
Monitoring and counseling
Assess diagnostic fit, adherence, local reaction and response.
Monitoring priorities
Confirm oral infection and assess immunocompromised prophylaxis context; follow hepatic function for lozenges. Review tacrolimus levels/renal symptoms through transplant team with interacting-medication changes. Skin nonresponse needs diagnosis/microbiology review; vaginal first/recurrent or red-flag symptoms require assessment. Clotic needs eardrum/age evaluation and review if symptoms do not improve after 14 days. No universal laboratory timetable invented.
Counseling
Use only intended route and exact duration. Dissolve lozenges slowly; do not give to someone unable to follow instructions. Keep skin clean/dry, avoid occlusion and reinfection, and follow product course. Vaginal: follow applicator instructions and barrier-device/intercourse restrictions. Clotic: warm vial in hand, use entire dose, keep ear upward 1 minute and discard immediately; avoid objects in ear canal. Keep away from children and seek medical advice for swallowed products.
Product identification
Single-ingredient strengths do not identify an interchangeable vehicle.
Representative 10 mg mouth lozenge
- Appearance
- White discoid uncoated lozenge; PAD over 0107 on one side.
- Packages
- Padagis 70-lozenge bottle NDC 0574-0107-70; other selected packages 140 or 70 foil packs.
- Status / route
- Prescription local oral troche; not a systemic antifungal tablet.
Dosage forms and strengths
- Skin
- 1% =10 mg/g cream; prescription Glenmark and selected OTC Drug Facts have distinct indications/course instructions.
- Vaginal
- 1% gives 50 mg per full applicator for 7 days; selected 2% gives 100 mg per full applicator for 3 days. Use their own applicators.
- Clotic otic
- Sterile preservative-free 1% in PEG 400;0.17 mL deliverable volume =1.7 mg per single-dose vial. Carton 28 vials, NDC 15370-220-28; prescription NDA 217628.
- Excluded combinations
- Clotrimazole/betamethasone or other combinations, unverified solutions/tablets and international products need separate source review; no current-stock claims.
Storage and handling
Lozenges 20–25°C, avoid freezing and dispense tightly closed. Selected skin creams 2–30°C; vaginal creams 20–25°C with intact seal/expiration review. Clotic 20–25°C with brief 15–30°C excursions; keep unopened vials in foil against humidity, use opened vial immediately and discard after use; discard unused vials 30 days after first pouch opening. Do not apply this otic discard period to other products.
References
Original sources for the clinical and product information.
- DailyMed / official U.S. product labelingClotrimazole 10 mg lozenges · Padagis full label
Clinical footer Rev 05-22A; current served SPL API publication December 2023; SPL v 6 effective 20220531; API publication Dec 04, 2023. Clinical revision is distinct from publication. Checked October 1, 2026.
- DailyMed / official U.S. product labelingClotrimazole 1% prescription skin cream · Glenmark
Clinical footer May 2025; SPL v 8 effective 20260130; API publication Feb 02, 2026. Clinical revision is distinct from publication. Checked October 1, 2026.
- DailyMed / official U.S. product labelingClotrimazole 1% OTC skin cream · Taro/Preferred
Current full Drug Facts; no separate clinical revision printed; SPL v 5 effective 20260401; API publication Apr 02, 2026. Clinical revision is distinct from publication. Checked October 1, 2026.
- DailyMed / official U.S. product labelingClotrimazole 1% vaginal cream · Taro/Preferred
Current full 7-day Drug Facts; no separate clinical revision printed; SPL v 9 effective 20260331; API publication Apr 02, 2026. Clinical revision is distinct from publication. Checked October 1, 2026.
- DailyMed / official U.S. product labelingClotrimazole 2% vaginal cream · Sun/Ohm
Current full 3-day Drug Facts and educational brochure; brochure code 0125 is not asserted as formal PI revision; SPL v 5 effective 20250702; API publication Jul 04, 2025. Clinical revision is distinct from publication. Checked October 1, 2026.
- DailyMed / official U.S. product labelingClotic 1% otic solution · Carwin full label
Clinical PI/Patient Information October 2025; later March 2026 SPL publication distinct; SPL v 1 effective 20260303; API publication Mar 10, 2026. Clinical revision is distinct from publication. Checked October 1, 2026.
- DailyMed / official U.S. product labelingPrograf · current primary clotrimazole interaction context
Full 2.6/5.5/7.2 only for tacrolimus interaction/monitoring; no transplant regimen transplanted; SPL v 30 effective 20230825; API publication Mar 21, 2025. Clinical revision is distinct from publication. Checked October 1, 2026.